Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Consider endocrine and metabolic effects when selecting an antipsychotic, then monitor and manage accordingly

    This is a preview of subscription content, log in to check access.

    Table I

    References

    1. 1.

      Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia: second edition [online]. Available from URL: http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=Schizophrenia2e_Inactivated_04-16-09 [Accessed 2010 Apr 29]

    2. 2.

      American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 Feb; 27(2): 596–601

    3. 3.

      Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64(20): 2291–314

    4. 4.

      Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry 2007; 68Suppl. 4: 14–8

    5. 5.

      Bhuvaneswar CG, Baldessarini RJ, Harsh VL, et al. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs 2009; 23(12): 1003–21

    6. 6.

      Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004 Aug; 161(8): 1334–49

    7. 7.

      Ma RC, Kong AP, Chan N, et al. Drug-induced endocrine and metabolic disorders. Drug Saf 2007; 30(3): 215–45

    8. 8.

      Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007; 68Suppl. 4: 8–13

    9. 9.

      Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract 2007 Aug; 61(8): 1356–70

    10. 10.

      Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidaemia. J Clin Psychiatry 2007; 68Suppl. 4: 34–9

    11. 11.

      Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep 22; 353(12): 1209–23

    12. 12.

      Meulendijks D, Mannesse CK, Jansen PAE, et al. Antipsychotic-induced hyponatraemia: a systematic review of the published evidence. Drug Saf 2010; 33(2): 101–14

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Consider endocrine and metabolic effects when selecting an antipsychotic, then monitor and manage accordingly. Drugs Ther. Perspect 26, 24–26 (2010). https://doi.org/10.2165/11205280-000000000-00000

    Download citation